Literature DB >> 31289972

Clinical application of stress echocardiography for valvular heart disease.

Kenya Kusunose1.   

Abstract

Stress echocardiography is widely used to assess several cardiovascular diseases, including ischemic heart disease, valvular heart disease (VHD), heart failure, congenital heart disease, and pulmonary hypertension. In valvular heart disease with asymptomatic severe or symptomatic non-severe status, stress echocardiography plays a central role in the management. As of 2017, the updated American College of Cardiology/American Heart Association and European Society of Cardiology/European Association for Cardio-Thoracic Surgery VHD guidelines recommended stress testing to (1) confirm symptoms and (2) evaluate the hemodynamic response to exercise. In patients with undetermined VHD severity in the presence of low-flow status, it can also be helpful to determine whether the VHD is severe based on flow-dependent changes in response to stress. The clinical indications of stress echocardiography in VHD have expanded with growing evidence for prognosis and being an early marker for interventions. As a result, demand has increased in major cardiology societies for the standardization of stress echocardiography in VHD. Echocardiographic centers should be aware of the clinical potential of stress echocardiography to ensure its optimal application and performance in VHD. This article reviews the clinical application of stress echocardiography, including dobutamine, semisupine bicycle, treadmill, and leg-positive pressure for VHD patient management, and focuses on the current consensus regarding the use of stress echocardiography in VHD. Stress echocardiography is safe and should be encouraged, especially in heart valve clinics, to understand the complex mechanism in asymptomatic patients.

Entities:  

Keywords:  Dobutmaine; Echocardiography; Semisupine bicycle; Stress echocardiography; Treadmill

Mesh:

Year:  2019        PMID: 31289972     DOI: 10.1007/s10396-019-00958-y

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  33 in total

Review 1.  Dynamic assessment of stenotic valvular heart disease by stress echocardiography.

Authors:  Sanjeev Bhattacharyya; Rajdeep Khattar; Nav Chahal; Neil Moat; Roxy Senior
Journal:  Circ Cardiovasc Imaging       Date:  2013-07       Impact factor: 7.792

2.  Pre-load stress echocardiography for predicting the prognosis in mild heart failure.

Authors:  Hirotsugu Yamada; Kenya Kusunose; Susumu Nishio; Mika Bando; Junko Hotchi; Shuji Hayashi; Takayuki Ise; Shusuke Yagi; Koji Yamaguchi; Takashi Iwase; Takeshi Soeki; Tetsuzo Wakatsuki; Masataka Sata
Journal:  JACC Cardiovasc Imaging       Date:  2014-06-18

3.  RV Myocardial Strain During Pre-Load Augmentation Is Associated With Exercise Capacity in Patients With Chronic HF.

Authors:  Kenya Kusunose; Hirotsugu Yamada; Susumu Nishio; Ayumi Ishii; Yukina Hirata; Hiromitsu Seno; Yoshihito Saijo; Takayuki Ise; Koji Yamaguchi; Shusuke Yagi; Takeshi Soeki; Tetsuzo Wakatsuki; Masataka Sata
Journal:  JACC Cardiovasc Imaging       Date:  2017-07-19

4.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

5.  Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation.

Authors:  Julien Magne; Patrizio Lancellotti; Luc A Piérard
Journal:  Circulation       Date:  2010-06-21       Impact factor: 29.690

Review 6.  Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group.

Authors:  Julien Magne; Philippe Pibarot; Partho P Sengupta; Erwan Donal; Raphael Rosenhek; Patrizio Lancellotti
Journal:  JACC Cardiovasc Imaging       Date:  2015-01

7.  Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation.

Authors:  Julien Magne; Erwan Donal; Haifa Mahjoub; Beatrice Miltner; Raluca Dulgheru; Christophe Thebault; Luc A Pierard; Philippe Pibarot; Patrizio Lancellotti
Journal:  Heart       Date:  2014-10-17       Impact factor: 5.994

8.  Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function.

Authors:  R O Bonow; E Lakatos; B J Maron; S E Epstein
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

9.  Preload Stress Echocardiography Predicts Outcomes in Patients With Preserved Ejection Fraction and Low-Gradient Aortic Stenosis.

Authors:  Kenya Kusunose; Hirotsugu Yamada; Susumu Nishio; Yuta Torii; Yukina Hirata; Hiromitsu Seno; Yoshihito Saijo; Takayuki Ise; Koji Yamaguchi; Shusuke Yagi; Takeshi Soeki; Tetsuzo Wakatsuki; Masataka Sata
Journal:  Circ Cardiovasc Imaging       Date:  2017-10       Impact factor: 7.792

Review 10.  Consensus recommendations for echocardiography in adults with congenital heart defects from the International Society of Adult Congenital Heart Disease (ISACHD).

Authors:  Wei Li; Cathy West; Jackie McGhie; Annemien E van den Bosch; Sonya V Babu-Narayan; Folkert Meijboom; Francois-Pierre Mongeon; Paul Khairy; Thomas R Kimball; Luc M Beauchesne; Naser M Ammash; Gruschen R Veldtman; Erwin Oechslin; Michael A Gatzoulis; Gary Webb
Journal:  Int J Cardiol       Date:  2018-07-11       Impact factor: 4.164

View more
  2 in total

Review 1.  Review: application of current imaging modalities in the management of left-sided valvular heart disease.

Authors:  Robert Zheng; Kenya Kusunose
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 2.  The contemporary role of echocardiography in the assessment and management of aortic stenosis.

Authors:  Takeshi Kitai; Rayji S Tsutsui
Journal:  J Med Ultrason (2001)       Date:  2019-12-02       Impact factor: 1.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.